Synthesis and evaluation of 4-[18F]fluorothalidomide for the in vivo studies of angiogenesis

Nuclear Medicine and Biology

Volumn 33, Issue 2, 2006, Pages 255-262

  Kim, Dong Hyun ^a   Choe, Yearn Seong ^a   Jung, Kyoung Ho ^a   Lee, Kyung Han ^a   Choi, Yong ^a   Kim, Byung Tae ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

4 18F Fluorothalidomide; Angiogenesis; HUVEC; In vitro metabolism; PET

Indexed keywords

4 FLUOROTHALIDOMIDE F 18; FLUORODEOXYGLUCOSE F 18; THALIDOMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EVALUATION; HUMAN; HUMAN CELL; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; LUNG CARCINOMA; MASS SPECTROMETRY; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOASSAY; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SYNTHESIS;

ANIMALS; CARCINOMA, LEWIS LUNG; ENDOTHELIAL CELLS; HUMANS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; THALIDOMIDE; TISSUE DISTRIBUTION;

EID: 33644941740     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.12.003     Document Type: Article

References (28)

1. J. Folkman The role of angiogenesis in tumor growth Semin Cancer Biol 3 1992 65 71
2. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
3. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
4. A. Bamias, and M.A. Dimopoulos Angiogenesis in human cancer: implications in cancer therapy Eur J Intern Med 14 2003 459 469
5. J. Fayette, J.-C. Soria, and J.-P. Armand Use of angiogenesis inhibitors in tumour treatment Eur J Cancer 41 2005 1109 1116
6. S. Liekens, E. De Clercq, and J. Neyts Angiogenesis: regulators and clinical applications Biochem Pharmacol 6 2001 253 270
7. R.J. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 1994 4082 4085
8. S. Sleijfer, W.H.J. Kruit, and G. Stoter Thalidomide in solid tumours: the resurrection of an old drug Eur J Cancer 40 2004 2377 2382
9. S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, and P. Eddlemon Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
10. A. Kneller, P. Raanani, I. Hardan, A. Avigdor, I. Levi, and M. Berkowitz Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug Br J Haematol 108 2000 391 393
11. V. Eleutherakis-Papaiakovou, A. Bamias, and M.A. Dimopoulos Thalidomide in cancer medicine Ann Oncol 15 2004 1151 1160
12. S.M. Baidas, E.P. Winer, G.F. Fleming, L. Harris, J.M. Pluda, and J.G. Crawford Phase II evaluation of thalidomide in patients with metastatic breast cancer J Clin Oncol 18 2000 2710 2717
13. W.D. Figg, W. Dahut, P. Duray, M. Hamilton, A. Tompkins, and S.M. Steinberg A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer Clin Cancer Res 7 2001 1888 1893
14. L. Dal Lago, M.F. Richter, A.I. Cancela, S.A. Fernandes, K.T. Jung, and A.C. Rodrigues Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer Invest New Drugs 21 2003 359 366
15. G.M. Marx, N. Pavlakis, S. McCowatt, F.M. Boyle, J.A. Levi, and D.R. Bell Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme J Neurooncol 54 2001 31 38
16. J. Stebbing, C. Benson, and T. Eisen The treatment of advanced renal cell cancer with high-dose of thalidomide Br J Cancer 85 2001 953 958
17. S.-Y. Lee, Y.S. Choe, D.H. Kim, B.-N. Park, S.E. Kim, and Y. Choi A simple and efficient in vitro method for metabolism studies of radiotracers Nucl Med Biol 28 2001 391 395
18. 18F-labeled 1-phenylpiperazine using mouse liver S9 fraction Nucl Med Biol 33 2006 165 172
19. G.W. Muller, R. Chen, S.-Y. Huang, L.G. Corral, L.M. Wong, and R.T. Patterson Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production Bioorg Med Chem Lett 9 1999 1625 1630
20. L.M. Lima, P. Castro, A.L. Machado, C.A.M. Fraga, C. Lugnier, and V.L. Goncalves de Moraes Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues Bioorg Med Chem 10 2002 3067 3073
21. W.R. Banks, R.D. Borchert, and D.R. Hwang Improvements in the production of flurorine-18 labelled butyrophenone neuroleptic agents Appl Radiat Isot 45 1994 75 81
22. 18F]GBR-13119 J Labelled Compd Radiopharm 27 1989 823 833
23. T. Takaku, Y. Kimura, and H. Okuda Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action J Nutr 131 2001 1409 1413
24. J. Lu, N. Helsby, B.D. Palmer, M. Tingle, B.C. Baguley, and P. Kestell Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans J Pharmacol Exp Ther 310 2004 571 577
25. M.G. Marks, J. Shi, M.O. Fry, Z. Xiao, M. Trzyna, and V. Pokala Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation Biol Pharm Bull 25 2002 597 604
26. K.S. Bauer, S.C. Dixon, and W.D. Figg Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent Biochem Pharmacol 55 1998 1827 1834
27. S.K. Teo, P.J. Sabourin, K. O'Brien, K.A. Kook, and S.D. Thomas Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients J Biochem Mol Toxicol 14 2000 140 147
28. S. Tseng, G. Pak, K. Washenik, M.K. Pomeranz, and J.L. Shupack Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses J Am Acad Dermatol 35 1996 969 979